NVAX logo

Novavax, Inc. (NVAX) Accounts receivable

Annual accounts receivable:

$108.28M-$188.96M(-63.57%)
December 31, 2024

Summary

  • As of today (September 3, 2025), NVAX annual accounts receivable is $108.28 million, with the most recent change of -$188.96 million (-63.57%) on December 31, 2024.
  • During the last 3 years, NVAX annual accounts receivable has fallen by -$346.71 million (-76.20%).
  • NVAX annual accounts receivable is now -76.20% below its all-time high of $454.99 million, reached on December 31, 2021.

Performance

1-year change

-63.57%

3-year change

-76.2%

5-year change

+1343.8%

15-year change

-

NVAX Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

73.06%
NVAX annual accounts receivable is higher than 73.06% of companies in Healthcare sector

Range

All-time high

$454.99M
NVAX annual accounts receivable is currently -76.20% below its historical high of $454.99 million

3-year low

$82.38M
NVAX annual accounts receivable is currently +31.45% above its 3-year low

Earnings dates

Last annual earnings report date

Dec 31, 2024
NVAX previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
NVAX next annual earnings announcement has not yet been scheduled

OtherNVAXbalance sheet metrics

annual accounts payable

$41.58M
NVAX annual accounts payable is $41.58 million

annual total assets

$1.60B
NVAX annual total assets is $1.60 billion

annual total liabilities

$2.23B
NVAX annual total liabilities is $2.23 billion

annual cash & cash equivalents

$933.74M
NVAX annual cash & cash equivalents is $933.74 million

Quarterly accounts receivable:

$226.40M+$181.89M(+408.64%)
June 30, 2025

Summary

  • As of today (September 3, 2025), NVAX quarterly accounts receivable is $226.40 million, with the most recent change of +$181.89 million (+408.64%) on June 30, 2025.
  • Over the past year, NVAX quarterly accounts receivable has increased by +$194.29 million (+605.17%).
  • NVAX quarterly accounts receivable is now -52.65% below its all-time high of $478.16 million, reached on March 31, 2022.

Performance

3-month change

+408.64%

1-year change

+605.17%

3-year change

+16.38%

5-year change

+100%

NVAX Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

80.24%
NVAX quarterly accounts receivable is higher than 80.24% of companies in Healthcare sector

Range

All-time high

$478.16M
NVAX quarterly accounts receivable is currently -52.65% below its historical high of $478.16 million

3-year low

$21.38M
NVAX quarterly accounts receivable is currently +958.91% above its 3-year low

Earnings dates

Last quarterly earnings report date

Jun 30, 2025
NVAX previous earnings announcement was published on Jun 30, 2025

Next quarterly earnings report date

Nov 10, 2025
NVAX next earnings announcement is scheduled for Nov 10, 2025

OtherNVAXbalance sheet metrics

quarterly accounts payable

$50.59M
NVAX quarterly accounts payable is $50.59 million

quarterly total assets

$1.34B
NVAX quarterly total assets is $1.34 billion

quarterly total liabilities

$1.30B
NVAX quarterly total liabilities is $1.30 billion

quarterly cash & cash equivalents

$253.74M
NVAX quarterly cash & cash equivalents is $253.74 million

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

NVAX Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-63.6%+605.2%
3 y3 years-76.2%+16.4%
5 y5 years+1343.8%+100.0%

NVAX Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-76.2%+31.4%-42.7%+958.9%
5 y5-year-76.2%+1343.8%-52.6%>+9999.0%
alltimeall time-76.2%>+9999.0%-52.6%>+9999.0%

NVAX Accounts receivable History

DateAnnualQuarterly
Jun 2025
-
$226.40M(+408.6%)
Mar 2025
-
$44.51M(-58.9%)
Dec 2024
$108.28M(-63.6%)
$108.28M(+14.0%)
Sep 2024
-
$94.96M(+195.8%)
Jun 2024
-
$32.10M(+50.2%)
Mar 2024
-
$21.38M(-92.8%)
Dec 2023
$297.24M(+260.8%)
$297.24M(+140.4%)
Sep 2023
-
$123.66M(-68.7%)
Jun 2023
-
$394.89M(+249.9%)
Mar 2023
-
$112.85M(+37.0%)
Dec 2022
$82.38M(-81.9%)
$82.38M(-26.2%)
Sep 2022
-
$111.64M(-42.6%)
Jun 2022
-
$194.53M(-59.3%)
Mar 2022
-
$478.16M(+5.1%)
Dec 2021
$454.99M(+73.7%)
$454.99M(+313.8%)
Sep 2021
-
$109.96M(+54.1%)
Jun 2021
-
$71.36M(-30.2%)
Mar 2021
-
$102.19M(-61.0%)
Dec 2020
$262.01M(+3393.5%)
$262.01M(+1519.3%)
Sep 2020
-
$16.18M(>+9900.0%)
Jun 2020
-
$0.00(0.0%)
Mar 2020
-
$0.00(-100.0%)
Dec 2019
$7.50M(+3118.9%)
$7.50M(+3118.9%)
Dec 2016
$233.00K(-90.0%)
$233.00K(-60.6%)
Sep 2016
-
$591.00K(+62.8%)
Jun 2016
-
$363.00K(-10.6%)
Mar 2016
-
$406.00K(-82.5%)
Dec 2015
$2.32M(-78.1%)
$2.32M(-46.5%)
Sep 2015
-
$4.33M(-10.5%)
Jun 2015
-
$4.84M(-55.5%)
Mar 2015
-
$10.87M(+2.5%)
Dec 2014
$10.61M(+53.8%)
$10.61M(+271.1%)
Sep 2014
-
$2.86M(-66.6%)
Jun 2014
-
$8.56M(-19.1%)
Mar 2014
-
$10.58M(+53.3%)
Dec 2013
$6.90M(+167.3%)
$6.90M(+35.1%)
Sep 2013
-
$5.11M(+87.5%)
Jun 2013
-
$2.72M(-34.8%)
Mar 2013
-
$4.17M(+61.7%)
Dec 2012
$2.58M
$2.58M(+4.5%)
Sep 2012
-
$2.47M(+64.8%)
Jun 2012
-
$1.50M(-13.2%)
DateAnnualQuarterly
Mar 2012
-
$1.73M(-54.6%)
Dec 2011
$3.80M(+6938.9%)
$3.80M(-1.7%)
Sep 2011
-
$3.87M(+0.3%)
Jun 2011
-
$3.85M(+53.0%)
Mar 2011
-
$2.52M(+4561.1%)
Dec 2010
$54.00K(-79.1%)
$54.00K(-91.0%)
Sep 2010
-
$599.00K(+68.3%)
Jun 2010
-
$356.00K(+54.1%)
Mar 2010
-
$231.00K(-10.5%)
Dec 2009
$258.00K(-11.0%)
$258.00K(-21.8%)
Dec 2008
$290.00K(-56.5%)
-
Sep 2008
-
$330.00K(+0.9%)
Jun 2008
-
$327.00K(-49.5%)
Mar 2008
-
$647.00K(-59.6%)
Dec 2007
$667.00K(-47.6%)
-
Sep 2007
-
$1.60M(+103.4%)
Jun 2007
-
$787.00K(-13.1%)
Mar 2007
-
$906.00K(-28.9%)
Dec 2006
$1.27M(-64.3%)
$1.27M(-59.2%)
Sep 2006
-
$3.13M(-18.3%)
Jun 2006
-
$3.83M(+6.2%)
Mar 2006
-
$3.60M(+0.8%)
Dec 2005
$3.57M(+331.8%)
$3.57M(+211.3%)
Sep 2005
-
$1.15M(+1.2%)
Jun 2005
-
$1.13M(+81.0%)
Mar 2005
-
$626.00K(-24.3%)
Dec 2004
$827.00K(-57.8%)
$827.00K(-53.5%)
Sep 2004
-
$1.78M(-46.0%)
Jun 2004
-
$3.30M(+42.3%)
Mar 2004
-
$2.32M(+18.3%)
Dec 2003
$1.96M(+4.1%)
$1.96M(-31.5%)
Sep 2003
-
$2.86M(+52.8%)
Jun 2003
-
$1.87M(+47.3%)
Mar 2003
-
$1.27M(-32.5%)
Dec 2002
$1.88M(-51.5%)
$1.88M(+24.3%)
Sep 2002
-
$1.51M(-53.7%)
Jun 2002
-
$3.27M(-16.1%)
Mar 2002
-
$3.90M(+0.6%)
Dec 2001
$3.88M
$3.88M(+28.8%)
Sep 2001
-
$3.01M(+20.7%)
Jun 2001
-
$2.50M(+44.6%)
Mar 2001
-
$1.73M

FAQ

  • What is Novavax, Inc. annual accounts receivable?
  • What is the all time high annual accounts receivable for Novavax, Inc.?
  • What is Novavax, Inc. annual accounts receivable year-on-year change?
  • What is Novavax, Inc. quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Novavax, Inc.?
  • What is Novavax, Inc. quarterly accounts receivable year-on-year change?

What is Novavax, Inc. annual accounts receivable?

The current annual accounts receivable of NVAX is $108.28M

What is the all time high annual accounts receivable for Novavax, Inc.?

Novavax, Inc. all-time high annual accounts receivable is $454.99M

What is Novavax, Inc. annual accounts receivable year-on-year change?

Over the past year, NVAX annual accounts receivable has changed by -$188.96M (-63.57%)

What is Novavax, Inc. quarterly accounts receivable?

The current quarterly accounts receivable of NVAX is $226.40M

What is the all time high quarterly accounts receivable for Novavax, Inc.?

Novavax, Inc. all-time high quarterly accounts receivable is $478.16M

What is Novavax, Inc. quarterly accounts receivable year-on-year change?

Over the past year, NVAX quarterly accounts receivable has changed by +$194.29M (+605.17%)
On this page